Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.

Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S.

Oncoimmunology. 2019 Jul 13;8(9):e1638210. doi: 10.1080/2162402X.2019.1638210. eCollection 2019.

2.

Immune cell phenotype and functional defects in Netherton syndrome.

Eränkö E, Ilander M, Tuomiranta M, Mäkitie A, Lassila T, Kreutzman A, Klemetti P, Mustjoki S, Hannula-Jouppi K, Ranki A.

Orphanet J Rare Dis. 2018 Nov 26;13(1):213. doi: 10.1186/s13023-018-0956-6.

3.

Limits for Resolving Isobaric Tandem Mass Tag Reporter Ions Using Phase-Constrained Spectrum Deconvolution.

Kelstrup CD, Aizikov K, Batth TS, Kreutzman A, Grinfeld D, Lange O, Mourad D, Makarov AA, Olsen JV.

J Proteome Res. 2018 Nov 2;17(11):4008-4016. doi: 10.1021/acs.jproteome.8b00381. Epub 2018 Sep 28.

4.

Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner.

Kreutzman A, Colom-Fernández B, Jiménez AM, Ilander M, Cuesta-Mateos C, Pérez-García Y, Arévalo CD, Brück O, Hakanen H, Saarela J, Ortega-Carrión A, de Rosendo A, Juanes-García A, Steegmann JL, Mustjoki S, Vicente-Manzanares M, Muñoz-Calleja C.

Clin Cancer Res. 2017 Nov 1;23(21):6697-6707. doi: 10.1158/1078-0432.CCR-16-0667. Epub 2017 Aug 18.

5.

Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

Arteche-López A, Kreutzman A, Alegre A, Sanz Martín P, Aguado B, González-Pardo M, Espiño M, Villar LM, García Belmonte D, de la Cámara R, Muñoz-Calleja C.

Bone Marrow Transplant. 2017 Jun;52(6):832-838. doi: 10.1038/bmt.2017.29. Epub 2017 Apr 3.

PMID:
28368375
6.

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brümmendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevärn B, Olsson-Strömberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1543-1554. doi: 10.1007/s00432-017-2378-6. Epub 2017 Mar 23.

PMID:
28337541
7.

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

El Missiry M, Hjorth-Hansen H, Richter J, Olson-Strömberg U, Stenke L, Porkka K, Kreutzman A, Mustjoki S.

PLoS One. 2017 Jan 30;12(1):e0171041. doi: 10.1371/journal.pone.0171041. eCollection 2017.

8.

A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD.

Portero-Sainz I, Gómez-García de Soria V, Cuesta-Mateos C, Fernández-Arandojo C, Vega-Piris L, Royg M, Colom-Fernández B, Marcos-Jiménez A, Somovilla-Crespo B, Ramírez-Mengíbar A, López-Huete V, de Rosendo-Serrano A, Kreutzman A, Muñoz-Calleja C.

Bone Marrow Transplant. 2017 May;52(5):745-752. doi: 10.1038/bmt.2016.342. Epub 2017 Jan 23.

PMID:
28112745
9.

T cells and cancer - why do the killers become exhausted?

Brück O, Keränen M, Dufva O, Kreutzman A, Mustjoki S.

Duodecim. 2016;132(21):1984-92. Review.

PMID:
29190050
10.

Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.

Cuesta-Mateos C, Loscertales J, Kreutzman A, Colom-Fernández B, Portero-Sáinz I, Pérez-Villar JJ, Terrón F, Muñoz-Calleja C.

Cancer Immunol Immunother. 2015 Jun;64(6):665-76. doi: 10.1007/s00262-015-1670-z. Epub 2015 Feb 28.

PMID:
25724841
11.

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells.

Kreutzman A, Ilander M, Porkka K, Vakkila J, Mustjoki S.

Oncoimmunology. 2014 May 29;3:e28925. eCollection 2014.

12.

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia.

Ilander M, Kreutzman A, Mustjoki S.

Oncoimmunology. 2014 Apr 29;3:e28781. eCollection 2014.

13.

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.

Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, Vakkila J, Mustjoki S.

PLoS One. 2014 Jan 31;9(1):e87794. doi: 10.1371/journal.pone.0087794. eCollection 2014.

14.

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, Remes K, Lundán T, Hjorth-Hansen H, Vakkila J, Simonsson B, Mustjoki S, Porkka K.

Eur J Haematol. 2014;92(5):413-20. doi: 10.1111/ejh.12258. Epub 2014 Jan 28.

PMID:
24372965
15.

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, Smykla R, Lee FY, Vakkila J, Jalkanen S, Salmi M, Porkka K.

Leukemia. 2013 Apr;27(4):914-24. doi: 10.1038/leu.2012.348. Epub 2012 Nov 29.

PMID:
23192016
16.

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Kreutzman A, Jaatinen T, Greco D, Vakkila E, Richter J, Ekblom M, Hjorth-Hansen H, Stenke L, Melo T, Paquette R, Seggewiss-Bernhardt R, Guerci-Bresler A, Talbot A, Cayuela JM, Mahon FX, Porkka K, Lipton J, Partanen J, Rousselot P, Mustjoki S.

Exp Hematol. 2012 Nov;40(11):906-913.e1. doi: 10.1016/j.exphem.2012.07.007. Epub 2012 Jul 25.

PMID:
22842045
17.

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, Arstila P, Porkka K, Mustjoki S.

PLoS One. 2011;6(8):e23022. doi: 10.1371/journal.pone.0023022. Epub 2011 Aug 9.

18.

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA, Mustjoki S, Seggewiss R.

Leukemia. 2011 Oct;25(10):1587-97. doi: 10.1038/leu.2011.135. Epub 2011 Jun 7.

PMID:
21647156
19.

Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.

Jalkanen SE, Vakkila J, Kreutzman A, Nieminen JK, Porkka K, Mustjoki S.

Exp Hematol. 2011 Jan;39(1):102-113.e1. doi: 10.1016/j.exphem.2010.09.005. Epub 2010 Oct 12.

PMID:
20869423
20.

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S.

Blood. 2010 Aug 5;116(5):772-82. doi: 10.1182/blood-2009-12-256800. Epub 2010 Apr 22.

PMID:
20413659

Supplemental Content

Loading ...
Support Center